Long-term management of scalp psoriasis: Perspectives from the international psoriasis council

Journal of Dermatological Treatment

Volumn 24, Issue 3, 2013, Pages 188-192

  Kragballe, Knud ^a   Menter, Alan ^b   Lebwohl, Mark ^c   Tebbey, Paul W ^d   Van De Kerkhof, Peter C M ^e  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d International Psoriasis Council   (United States)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adherence; Quality of life; Systemic; Topical

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; CLOBETASOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; DITHRANOL; KERATOLYTIC AGENT; PLACEBO; SHAMPOO; TACALCITOL; TAR; VITAMIN D DERIVATIVE;

CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SCALP; SKIN ATROPHY; SKIN IRRITATION; TELANGIECTASIA;

ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; DERMATOLOGIC AGENTS; HAIR PREPARATIONS; HUMANS; LONG-TERM CARE; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PSORIASIS; QUALITY OF LIFE; SCALP DERMATOSES; VITAMIN D;

EID: 84877078273     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2012.681017     Document Type: Review

References (32)

1. Kaur I, Handa S, Kumar B. Natural history of psoriasis: A study from the Indian subcontinent. J Dermatol. 1997;24:230-234.
2. Wozel G. Psoriasis treatment in difficult locations: Scalp, nails, and intertriginous areas. Clin Dermatol. 2008;26:448-459.
3. Griffiths CE, Christophers E, Barker JN, Chalmers RJ, Chimenti S, Krueger GG, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol. 2007;156:258-262.
4. van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology. 1998;197:326-334.
5. Poulin Y, Papp K, Bissonnette R, Guenther L, Tan J, Lynde C, et al. Clobetasol propionate shampoo 0.05% is efficaceous and safe for long-term control of scalp psoriasis. Cutis. 2010;85:43-50.
6. Barnes L, Altmeyer P, Forstrom L, et al. Long-term treatment of psoriasis with psoriasis scalp solution and cream. Eur J Dermatol. 2000;10:199-204.
7. Jemec BBE, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomized double-blind, controlled study. J Am Acad Dermatol. 2008;59:455-463.
8. Van de Kerkhof PCM, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriol plus betamthasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: A randomized, double-blind controlled trial. Br J Dermatol. 2009;160:170-176.
9. Kragballe K, Hoffmann V, Ortonne JP, et al. Efficacy and safety calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: A randomized controlled trial. Br J Dermatol. 2009;161:159-166.
10. Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology. 2008;217:321-328.
11. Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2009;60:962-971.
12. Ortonne JP, Chimenti S, Puig L, et al. Scalp Psoriasis: European consensus on grading and treatment algorithm. J Eur Acad Dermatol Venereol. 2009;23:1435-1444.
13. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-284.
14. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CE. Quality of life in patients with psoriasis: The contribution of clinical variables and psoriasis-specific stress. Br J Dermatol. 1997;137:755-760.
15. Chen SC, Yeung J, Chren MM. Scalpdex: A quality-of-life instrument for scalp dermatitis. Arch Dematol. 2002;138:803-807.
16. Baer AH, Khanna V, Feldman SR. Literature is lacking in discussion of non-adherence in dermatology. J Dermatolog Treat. 2010;21:109-110.
17. Augustin M, Holland B, Dartsch D, et al. Adherence in the treatment of psoriasis: A systemic review. Dermatology. 2011;222:363-374.
18. Gokdemir G, Ari S, Köşlö A. Adherence to treatment in patients with psoriasis vulgaris: Turkish experience. J Eur Acad Dermatol Venereol. 2008;22:330-335.
19. Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55:607-613.
20. Storm A, Andersen SE, Benfeldt E, et al. One in 3 prescriptions are never redeemed: Primary nonadherence in an outpatient clinic. J Am Acad Dermatol. .2008;59:27-33.
21. Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol. 2007;57:81-83.
22. Carroll CL, Feldman SR, Camacho FT, et al. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: Commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51:212-216.
23. Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):9-14.
24. van de Kerkhof P, Kragballe K, Segaert S, Lebwohl M. Factors impacting the combination of topical corticosteroid therapies for psoriasis: Perspectives from the International Psoriasis Council. J Eur Acad Dermatol Venereol. 2011;25:1130-1139.
25. Feldman SR. Approaching psoriasis differently: Patient-physician relationships, patient education and choosing the right topical vehicle. J Drugs Dermatol. 2010;9:908-911.
26. Zivkovich AH, Feldman SR. Are ointments better than other vehicles for corticosteroid treatment of psoriasis? J Drugs Dermatol. 2009;8: 570-572.
27. Kurian A, Barankin B. Current effective topical therapies in the management of psoriasis. Skin Therapy Lett. 2011;16:4-7.
28. Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: A review of newer formulations. Am J Clin Dermatol. 2009;10:397-406.
29. Mrowietz U, Macheleidt O, Eicke C. Effective treatment and improvement of quality of life in patients with scalp psoriasis by topical use of calcipotriol/betamethasone (Xamiol-) gel: Results. J Dtsch Dermatol Ges. 2011;9:825-831.
30. Courtenay M, Carey N, Stenner K, et al. Patients' views of nurse prescribing: Effects on care, concordance and medicine taking. Br J Dermatol. 2011;164:396-401.
31. Ersser SJ, Cowdell FC, Nicholls PG. A pilot randomized controlled trial to examine the feasibility and efficacy of an educational nursing intervention to improve self-management practices in patients with mild-moderate psoriasis. J Eur Acad Dermatol Venereol. 2011; [Epub ahead of print].
32. Pouplard C, Gourraud PA, Meyer N, et al. Are we giving patients enough information on how to use topical treatments? Analysis of 767 prescriptions in psoriasis. Br J Dermatol. 2011;165:1332-1336.